Skip to Main Content
Contribute Try STAT+ Today

There’s an enzyme in the body that regulates what scientists refer to as “the bliss molecule,” a neurotransmitter associated with generally feeling good. And thus it made sense that blocking that enzyme, called FAAH, might be a useful way to combat feeling bad, like in cases of chronic pain or depression. 

And so a bunch of drug companies fashioned FAAH inhibitors and tested them in dozens of trials, only for each one to prove too weak or too toxic to become an actual medicine. This went on until around 2015, when the industry seemed to just move on from FAAH.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.